| |
sRAGE, pg/mL |
Pentosidinepg/mL |
AOPPs (μmol/l) |
| r |
P-value |
r |
P-value |
r |
P-value |
| Age (years) |
0.16 |
0.25 |
0.09 |
0.53 |
0.14 |
0.31 |
| Duration |
0.14 |
0.32 |
0.23 |
0.10 |
0.22 |
0.11 |
| Fasting blood glucse (mg/dl) |
0.33 |
0.01* |
0.39 |
0.005* |
0.28 |
0.04* |
| 2-h PP blood glucose (mg/dl) |
0.39 |
0.005* |
0.28 |
0.04* |
0.28 |
0.04 |
| HDL (mg/dl) |
-0.02 |
0.87 |
-0.25 |
0.07 |
-0.01 |
0.90 |
| TAG (mg/dl) |
0.06 |
0.66 |
0.25 |
0.07 |
0.26 |
0.06 |
| TC (mg/dl) |
0.40 |
0.004* |
0.29 |
0.04* |
0.33 |
0.01* |
| LDL (mg/dl) |
0.64 |
0.001* |
0.28 |
0.04* |
0.60 |
0.001* |
| Fasting insulin (μIU/ml) |
0.36 |
0.009* |
0.62 |
0.000* |
0.56 |
0.001* |
| HOMA-IR |
0.46 |
0.001* |
0.56 |
0.000* |
0.62 |
0.001* |
| UACR |
0.15 |
0.28 |
0.04 |
0.78 |
0.05 |
0.71 |
| Urea (mg %) |
0.51 |
0.000* |
0.30 |
0.03* |
0.11 |
0.42 |
| Serum creatinine (mg/dl) |
0.34 |
0.015* |
0.32 |
0.02* |
0.06 |
0.64 |
| estimated GFR (eGFR ,ml/min per 1.73m2) |
-0.12 |
0.39 |
-0.17 |
0.21 |
-0.08 |
0.58 |
| sRAGE, pg/mL |
|
|
0.63 |
0.001* |
0.52 |
0.001* |
| Pentosidinepg/mL |
0.63 |
0.001* |
|
|
0.59 |
0.001* |
| AOPPs |
0.52 |
0.001* |
0.59 |
0.001* |
|
|
| r= Pearson’s correlation coefficient, P was considered significant at <0.05.; *Significant
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, sRAGE: soluble receptor for advanced glycation end-products, AOPP:advanced oxidation protein products |
|
